Meridian Bioscience, Inc.
VIVO · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.34 | 0.37 | 0.12 |
| FCF Yield | -0.34% | -0.11% | 0.92% | 2.52% |
| EV / EBITDA | -50.32 | 152.42 | -581.16 | 26.94 |
| Quality | ||||
| ROIC | -7.80% | 1.47% | -1.73% | 6.95% |
| Gross Margin | 55.37% | 51.76% | 54.19% | 61.56% |
| Cash Conversion Ratio | 0.08 | 0.35 | -1.96 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.27% | 9.50% | 12.64% | 18.48% |
| Free Cash Flow Growth | -235.77% | -111.97% | -57.01% | -14.48% |
| Safety | ||||
| Net Debt / EBITDA | 1.53 | -5.66 | 23.09 | -1.07 |
| Interest Coverage | -195.60 | 22.06 | -24.79 | 108.14 |
| Efficiency | ||||
| Inventory Turnover | 0.35 | 0.47 | 0.44 | 0.60 |
| Cash Conversion Cycle | 272.18 | 206.92 | 218.36 | 164.21 |